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Abstract
Serine protease PRSS23 is a newly discovered protein that has been associated with tumor progression in various types of
cancers. Interestingly, PRSS23 is coexpressed with estrogen receptor a (ERa), which is a prominent biomarker and
therapeutic target for human breast cancer. Estrogen signaling through ERa is also known to affect cell proliferation,
apoptosis, and survival, which promotes tumorigenesis by regulating the production of numerous downstream effector
proteins. In the present study, we aimed to clarify the correlation between and functional implication of ERa and PRSS23 in
breast cancer. Analysis of published breast cancer microarray datasets revealed that the gene expression correlation
between ERa and PRSS23 is highly significant among all ERa-associated proteases in breast cancer. We then assessed
PRSS23 expression in 56 primary breast cancer biopsies and 8 cancer cell lines. The results further confirmed the
coexpression of PRSS23 and ERa and provided clinicopathological significance. In vitro assays in MCF-7 breast cancer cells
demonstrated that PRSS23 expression is induced by 17b-estradiol-activated ERa through an interaction with an upstream
promoter region of PRSS23 gene. In addition, PRSS23 knockdown may suppress estrogen-driven cell proliferation of MCF-7
cells. Our findings imply that PRSS23 might be a critical component of estrogen-mediated cell proliferation of ERa-positive
breast cancer cells. In conclusion, the present study highlights the potential for PRSS23 to be a novel therapeutic target in
breast cancer research.
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Introduction
Bioinformatics approaches have shown that the serine protease
23 gene (PRSS23) is highly conserved in vertebrates and is
predicted to encode a novel protease on chromosome 11q14.1 in
humans [1,2,3]. Previous expression-profiling studies have sug-
gested that enhanced PRSS23 expression is observed in various
types of cancers, including breast [4,5,6], prostate [7], papillary
thyroid [8], and pancreatic cancers [9], and the expression of the
PRSS23 has been linked with tumor progression in human [1]. In
addition, studies in MCF-7/BUS cells revealed that mRNA level
of PRSS23 may be stimulated by estrogen and reduced by
tamoxifen treatment [5,10].
Estrogen, which are well conserved in vertebrates, represents a
group of sex steroid hormones that include estradiol, estrone, and
estriol [11]. Although estrogen is the predominant sex hormone in
females, its levels are relatively low in males. Along with its role in
reproduction, estrogen also affects many cellular functions during
development and in adulthood. Ample evidence has shown that
estrogen and anti-estrogen agents, such as tamoxifen and
fulvestrant, can specifically bind to the ligand binding domain of
estrogen receptor a (ERa) to modulate differential expression of
downstream transcriptional targets of ERa in breast cancer cells.
These findings suggest that ERa could be a vital prognostic
biomarker in breast cancer [12,13,14,15,16,17].
Collective evidence suggests that estrogen signaling regulate a
variety of biological processes [18]. For instance, estrogen
signaling plays a pivotal role in growth and development of
mammary glands which is consistent with its role in normal sexual
and reproductive functions. Indeed, canonical estrogen signaling
affects the expression of specific downstream effector genes that
enhance cell survival via anti-apoptotic pathways. In addition,
estrogen signaling increases proliferation of breast cancer cells by
upregulating expression of cell cycle enhancers (e.g., cyclin D1)
and transcription factors (e.g., c-myc and E2F) expression in breast
cancer [19,20]. Although importance of novel ERa-related
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that estrogen could also enhance breast cancer cell progression
through intracellular proteases.
In the present study, we investigated the gene expression of the
ERa-related proteases in breast cancers. Our results indicate that
there was a high level of PRSS23 expression in ERa-positive
breast cancer cells. In addition, in vitro assays revealed that
PRSS23 expression was upregulated at the transcriptional level by
ERa and was associated with breast cancer cell proliferation.
Thus, PRSS23 might be a novel target for adjuvant therapy for
breast cancer progression.
Results
PRSS23 mRNA levels are correlated with ESR1 mRNA
expression in breast cancer
Our first aim was to screen for novel proteases that are
coregulated with ERa in breast cancer by mining the microarray
dataset published by van’t Veer et al. [21] Proteases including
CTSC (cathepsin C), CTSF, CTSL, CTSS, CTSL2, MMP-1
(matrix metalloprotease-1), MMP-7, MMP-9, MMP-12, MMP-24,
and PRSS23 that were associated with ESR1(mRNA of ERa)
expression. We then used hierarchy of correlation clustering to
examine the correlations between ESR1 and the candidate
protease genes. As shown in Fig. 1A, self-organized map analysis
revealed that the gene expression profiles of PRSS23, CTSC, and
CTSF were clustered within the group of ESR1 coregulated genes.
Other well-known estrogen-upregulated genes, like CDH (E-
cadherin), PGR (progesterone receptor), ERBB3 (V-erb-b2
erythroblastic leukemia viral oncogene homolog 3), ERBB4, and
GATA3 (GATA binding protein 3), were also found in the same
cluster. By comparison, CDKN2C (cyclin-dependent kinase
inhibitor 2C, p18), MMP-1, MMP-7, MMP-9, MMP-12, MMP-
24, CTSL, CTSL2, and CTSS were negatively correlated with
ESR1 mRNA levels. These findings were consistent with those
from regression analyses by van’t Veer et al.
We also compared the expression intensities of PRSS23, CTSC,
CTSF, and MMP-24 from 52 ERa-positive breast cancer
specimens within the van’t Veer dataset. The average expression
levels (log10 intensity) of PRSS23, CTSF, CTSC and MMP-24
were 0.779, 0.075, 21.101, and 21.434, respectively (Fig. 1B). In
addition to being significantly coregulated with ESR1 expression,
the present results suggest that there is greater mRNA expression
level of PRSS23 in breast cancer specimen than other well-known
Figure 1. Gene expression analysis of breast cancer patients. A. Clustering of self-organizing maps was done to analyze gene expression of
proteases, ESR1 and ESR1-coregulated genes among 90 breast cancer patients. The red-colored boxes represent upregulated genes (ratio of log10
intensity), and the green-colored boxes indicate downregulated genes. The cluster to the left shows the hierarchy relationship of gene expression
patterns, and the cluster at the top indicates correlation among groups of patient samples. The lowest box represents corresponding
immunohistochemistry results of ERa staining for each sample (open is positive, and filled is negative). B. The box plot showed expression intensity of
PRSS23, CTSF, CTSC, and MMP24 in 52 ERa-positive breast cancer specimens.
doi:10.1371/journal.pone.0030397.g001
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breast cancer has not been clearly characterized, we targeted
PRSS23 for further analysis in the present study.
High PRSS23 expression was observed in ERa-positive
breast cancer cells from breast cancer patients
To enable the detection of the PRSS23 protein, we raised an
antibody against PRSS23 by injecting recombinant GST-PRSS23
protein into a rabbit. After standard purification (the detailed
procedure is described in Materials and Methods S1), we validated
the efficacy and specificity of this custom anti-PRSS23 antibody by
immunoblot of protein from MCF-7 cells with or without ectopic
PRSS23 overexpression. Both endogenous and overexpressed
PRSS23 could be detected as a double-band pattern around
47 kDa (Fig. S1), which is close to PRSS23’s hypothetical
molecular weight (43 kDa).
We used the custom anti-PRSS23 antibody to perform
immunohistochemical assays on cancer specimens from 56
primary breast tumors collected in Taiwan. Interestingly, PRSS23
expression was detected in the nuclei of malignant breast tumor
tissues. To validate the relationship between PRSS23 and ERa
expression, we selected 6 representative sets of tumor samples from
breast cancer patients that were either ERa-positive (Fig. 2A, B, C)
or ERa-negative (Fig. 2D, E, F). Upon close examination, PRSS23
expression was found to be much higher in the nucleoplasm of
ERa-positive breast cancer specimens (Fig. 2G, H, I) compared
with the nucleoplasm of ERa-negative breast cancer specimens
(Fig. 2J, K, L).
For systemic comparison, the staining intensity of anti-PRSS23
in 56 Taiwan breast cancer samples was classified as strong (Fig.
S2A), moderate (Fig. S2B), or weak (Fig. S2C). This was
performed by comparing the staining intensity in the cancer
specimens to the intensity in normal cells in the vicinity of tumor
tissues. Specifically, we characterized PRSS23 staining by
comparing PRSS23 expression intensities in the nucleoplasm of
cancer cells to the expression intensities in normal stromal cells
and endothelial cells using the Allred immunohistochemistry score
system [22]. Based on the assigned total Allred scores, we grouped
the 56 breast cancer specimens into two cohorts: high PRSS23
expression (total Allred score.3), and the low PRSS23 expression
(total Allred Score 0–3) (Table 1). Strikingly, we found that nearly
75% of the ERa-positive breast cancer samples from Taiwanese
patients are belonged to the group with high PRSS23 expression
(Allred score.3). Conversely, over 80% of the ERa-negative
breast cancer samples belonged to the low PRSS23 expression
group (Allred score#3). Statistical analyses also indicated that
increased PRSS23 expression was significantly correlated with
ERa status of the cells (n=56, p=0.005).
Taken together, the results derived from the clinicopathological
and immunohistochemical analyses imply that PRSS23 expression
is closely related to ERa expression (Table 1). Interestingly, we did
not find any statistical significance between PRSS23 expression
and tumor invasion (p=0.56) or PRSS23 and HER-2 overex-
pression, which suggests that HER-2 amplification may not affect
PRSS23 expression (p=0.79).
PRSS23 is highly expressed in ERa-positive breast cancer
cell lines
Subsequently, we measured both mRNA and protein levels of
PRSS23 in 8 different human cell lines: 3 ERa-positive breast
cancer cell lines (MCF-7, BT-474, T-47D), 2 ERa-negative breast
cancer lines (Hs.578t, MDA-MB-231), 1 mammary epithelial cell
line (MCF-10A), 1 endometrial cell line (RL95-2), and 1 cervical
cancer line (Ca-SKi).
Positive expression of endogenous ERa was identified in MCF-
7, BT-474, and T-47D cells, which are all ERa-positive cancer cell
lines validated by anti-ERa staining. The results showed that ERa
was detected in MCF-7, BT-474, and T-47D cells (Fig. 3A).
Furthermore, by RT-qPCR survey, the normalized relative gene
expression level of PRSS23 was 0.2 in RL95-2 cells, 21.9 in MCF-
7 cells, 13.3 in BT-474 cells, 7.44 in T-47D cells, 0.14 in Hs.578t
cells, 1 in MDA-MB-231 cells, 1.12 in MCF-10A cells, and 2.58 in
Ca-Ski cells (Fig. 3B); all of the expression level was normalized to
the PRSS23 mRNA level in MDA-MB-231 cells.
Based on immunoblotting, expression of endogenous PRSS23
was identified in all cell lines utilized in this assay described above
by anti-PRSS23, and endogenous GAPDH staining served as the
loading control. The results showed that PRSS23 protein
expression was detected in ERa-positive MCF-7 cells, BT-474
cells, and T-47D cells (Fig. 3C). Quantification using densitometry
analysis revealed the expression level of PRSS23 to be 1 in MCF-7
cells, 0.18 in BT-474 cells, and 0.11 in T-47D cells (expression was
normalized to GAPDH expression in the respective cell line). The
results indicated that the expression level of PRSS23 was higher in
Figure 2. Expression of ERa and PRSS23 in human breast carcinoma. Immunohistochemical analysis revealed expression level of ERa (A, B,
C, D, E, F) and the corresponding PRSS23 expression of the same sample (G, H, I, J, K, L) in 6 different breast cancer specimens. The scale bar is
50 mm.
doi:10.1371/journal.pone.0030397.g002
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expression. These data from cell line survey also implicated that
ERa might upregulate expression of PRSS23 in agreement with
the microarray and immunohistochemical studies.
E2 upregulates PRSS23 expression in ERa-positive MCF-7
breast cancer cell
After learning that PRSS23 expression was correlated with ERa
in breast cancers, we investigated the dynamics of PRSS23
expression induced by estrogen stimulation. We treated the MCF-
7 cells with E2 and Tamoxifen (Tam) to test whether PRSS23
expression could be enhanced by activated ERa. We found that
PRSS23 mRNA expression increased significantly in MCF-7 cells
from 6, 12, and 24 h after E2 treatment (Fig. 4A). After 24 h of
treatment with 1 nM E2, PRSS23 mRNA expression was about
10-fold greater than the vehicle control (0.1% DMSO and 25 ppm
ethanol). By comparison, PRSS23 mRNA expression was
significantly reduced by 5 mM Tam treatment to a similar level
as the vehicle controls. In addition, Tam alone did not upregulate
PRSS23 mRNA levels in MCF-7 cells compared with the vehicle
control.
To confirm whether estrogen is indeed not able to upregulate
PRSS23 expression in ERa-negative cancer cells, we treated
MDA-MB-231 (ERa-negative) cells with 1 nM E2 and measured
the mRNA levels of PRSS23 and pS2, with the latter serving as a
positive control for estrogen responsiveness [23]. At 0, 6, 12 and
24 h after treatment, no significant correlationship was observed
in gene expression levels of PRSS23 in MDA-MB-231 cells treated
with 1 nM E2 compared with vehicle treated control (Fig. 4B
upper panel) as compared to pS2 (Fig. 4B lower panel). Although
the PRSS23 gene expression level in E2-treated cells is 3-fold higher
than that of vehicle treated control at 12 h. We hypothesized
PRSS23 expression might be regulated by alternative signaling
pathway in ER-negative MDA-MB-231 cells. Taken together,
these data suggest that PRSS23 expression is indeed primarily
regulated by estrogen signaling in ER-positive breast cancer cells.
Overexpression of ERa enhances PRSS23 expression in
MCF-7 cells
Based on the results described above, we hypothesized that ERa
protein level is relevant to the expression of PRSS23. Previous
studies have shown that ERa upregulates gene expression of pS2
and CTSD by recruiting estrogen, and E2-bound ERa is prone to
immediate ubiquitin-dependent degradation by the 20S protea-
somes after stabilizing transcription initiation [24,25,26,27]. To
assay whether a similar ERa stability issue could affect PRSS23
mRNA expression, we used MG-132 to perturb intracellular
proteasome activity in MCF-7 cells. When proteasome activity was
not disrupted by MG-132, ERa level appeared to be reduced in
E2-treated MCF-7 cells due to ubiquitin-dependent degradation
(Fig. 5A). Treatment with the proteasome inhibitor MG-132,
however, blocked the decrease in E2-induced ERa protein levels.
Furthermore, Tam could not induce ERa degradation in MCF-7
cells, which was consistent with findings from a previous study
Table 1. Clinicopathological characteristics and PRSS23
expression profile of breast cancer specimens.
Low PRSS23
expression
(score 0–3
{)
Higher PRSS23
expression
(score.3
{) p
{
Total 28 28 N.S.
Tumor size (cm)
* 2.9560.40 3.1260.51 0.79.
Lymph node invasion
+ 10 7 0.56
2 18 21
ERa (IHC)
+ 6 22 0.0001
2 22 6
HER2 (IHC)
+ 13 7 0.79.
2 15 21
Histological type
Ductal carcinoma 22 25 .
lobular carcinoma 0 0
Others 6 3
*Data are mean 6 SD.
{Total Allred score of proportion score and intensity score.
{p assessed using Fisher’s exact probability test.
doi:10.1371/journal.pone.0030397.t001
Figure 3. Expression analyses of PRSS23 in human cell lines.
Expression levels of PRSS23 as well as ERa were analyzed in eight
different cell lines: MCF-7, BT-474, Hs.578t, MDA-MB-231, T-47D (all
breast cancer), MCF-10A (mammary epithelial), RL95-2 (endometrial
cancer), and Ca-SKi (cervical cancer) cell lines. A. Immunoblot analysis
showed protein expression level of ERa in these human cell lines.
B. qRT-PCR analysis showed relative gene expression of PRSS23 mRNA
level. C. Immunoblot analysis showed protein expression level of
PRSS23 and GAPDH in these human cell lines. The cell lysate was loaded
20 mg protein for each well in immunoblot anaylsis. qRT-PCR was
performed in duplicate.
doi:10.1371/journal.pone.0030397.g003
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PLoS ONE | www.plosone.org 4 January 2012 | Volume 7 | Issue 1 | e30397Figure 4. E2-activated ERa enhances PRSS23 expression in MCF-7 cells. A. MCF-7 cells were treated with 1 nM E2, 25 ppm ethanol, 5 mM
Tam, and 0.5% dimethyl sulfoxide (DMSO) in phenol-red-free culture medium containing 10% CDS-FBS for 24 h. The bar plots depicted the results of
time-lapse profiling of PRSS23 mRNA levels at 6, 12, and 24 h. All experiments were performed in triplicate. The bars represent relative expression
levels of PRSS23 after treatment, which was normalized to the level of 6 h-treated cells (mean 6 S.E.M.). B. MDA-MB-231 cells were treated with 1 nM
E2 in phenol-red-free culture medium containing 10% CDS-FBS for 24 h. Expression of PRSS23 (upper panel) and pS2 (lower panel) was evaluated by
qRT-PCR at 0, 6, 12, and 24 h. The bars represented the gene expression levels of PRSS23 after treatment, which was normalized to the level of
untreated cells (mean 6 S.E.M.).
doi:10.1371/journal.pone.0030397.g004
Figure 5. Increased ERa level upregulated PRSS23 expression in MCF-7 cells. A. MCF-7 cells were treated with 1 nM E2, 1 mM Tam, or
vehicle (0.1% DMSO) in the absence or presence of 5 mg/ml MG-132. The immunoblot showed the protein levels of ERa, PRSS23 and GAPDH (20 mg
lysate protein/well). The bar chart represents the normalized protein level of PRSS23 to GAPDH loading control after 12 h treatment with 1 nM E2,
1 mM Tam, or vehicle. B. The bars represent gene expression levels of PRSS23 (upper panel) and pS2 (lower panel) in mean 6 S.E.M. C. MCF-7 cells
were transfected with ESR1 or vector for 12 h in culture medium containing 10% FBS. Protein levels of ERa and PRSS23 in the transfected MCF-7 cells
was determined by immunoblot analysis (20 mg lysate protein/well). The bar chart represented protein expression levels of PRSS23 normalized to
GAPDH. All experiments were performed in duplicate.
doi:10.1371/journal.pone.0030397.g005
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132 and E2 for 12 h could significantly increase the PRSS23
protein level in MCF-7 cells (near 1.5-fold) as compared with E2
treatment alone in the assay. Moreover, we also found the protein
level of PRSS23 significantly decreased near 0.5-fold to 0.6-fold in
Tam-treated MCF-7 cells whether MG-132 is present in the
medium or not.
We also found that cotreatment with MG-132 and E2 for 12 h
could increase the PRSS23 mRNA level (3-fold; Fig. 5B upper
panel) and pS2 level (1.3-fold; Fig. 5B lower panel) in MCF-7 cells
compared with treatment with E2 alone. Although MG-132
enhanced the PRSS23 mRNA level by 2.5-fold, cotreatment with
MG-132 and Tam reduced PRSS23 mRNA to a level similar to
untreated MCF-7 cells. These results suggest that the stability of
E2-activated ERa upregulates PRSS23 mRNA expression,
whereas Tam-inactivated ERa does not stimulate PRSS23
expression.
To clarify whether accumulation of ERa contributes exclusively
to the upregulation of PRSS23 expression, we ectopically
expressed ERa in MCF-7 cells. Fig. 5C shows that the PRSS23
protein level was increased ,1.5-fold in MCF-7 cells when ectopic
ERa was overexpressed. As expected, the enhancement was not
observed in the vector-only controls. Thus, these data suggest the
activity and stability of ERa are important for the regulation of
PRSS23 expression in MCF-7 cells.
E2 activates ERa to upregulate PRSS23 expression
through an upstream promoter region
Previous studies have suggested that ERa enhances downstream
gene expression through both genomic and non-genomic
pathways [19,28]. In addition, Moggs et al. postulated that a
consensus estrogen responsive element is located in the upstream
promoter region 22840 to 22828 bp from the translational start
site of the PRSS23 gene [23] To identify the critical estrogen
response region in the promoter region upstream of PRSS23,w e
used the genomic sequence from the NCBI Entrez Gene Database
to design a set of PCR primers, which were used to subclone
various promoter regions along with the upstream regulatory
region. Fig. 6A shows the luciferase reporter constructs that we
generated, which contained various regions across the PRSS23
promoter, including 22914 to 97 bp, 22029 to 97 bp, 21261 to
97 bp, and 2391 to 97 bp. We transfected MCF-7 cells with
individual reporter construct containing these variable promoter
sequences to screen for the most critical estrogen responsive
region. Interestingly, the normalized luciferase activities of the
22914 to 97 bp, 22029 to 97 bp, and 21261 to 97 bp constructs
increased by 35%, 40%, and 20% in E2-treated MCF-7 cells
compared with vehicle-treated cells, respectively (p,0.01, Fig. 6A).
By comparison, the normalized luciferase activity of the construct
containing the 2342 to 97 bp promoter region did not show
significant enhancement in E2-treated cells. Interestingly, the
difference in the luciferase activities between the 22914 to 97 bp
and 22029 to 97 bp constructs was not significant in the presence
of E2 (p.0.05); however, the luciferase activity of the 21261 to
97 bp construct was 11% lower than the activity of the 22914 to
97 bp construct (p,0.05). A more profound difference was
observed between the 21261 to 97 bp construct and the 22029
to 97 bp construct (p,0.05), in which the activity of 22029 to
97 bp construct was increased by 15% compared to that of 21261
to 97 bp construct in the presence of E2. Taken together, these
results suggest that ERa upregulates PRSS23 promoter activity
through different elements in the region within 22029 to 2342 bp
instead of through the hypothetical ERE (22840 to 22828 bp).
Based on the findings with the promoter region constructs, we
used ChIP assays to examine whether ERa directly binds to
promoter region upstream of the PRSS23 gene. The pS2 gene
served as a positive control. Fig. 6B shows that binding of ERa to
the upstream promoter region was enhanced in 10 nM E2-
stimulated MCF-7 cells after 60 min of treatment. Compared with
vehicle-treated controls, the strength of the interaction of ERa
with the upstream promoter region of the pS2 gene was 3-fold
higher, and that of PRSS23 gene after 60 min of treatment was
1.5-fold higher, which indicates that ERa upregulates PRSS23
expression through direct interaction via its upstream promoter
region.
PRSS23 expression is associated with estrogen-induced
proliferation in MCF-7 cells
Our earlier immunohistochemical data revealed that PRSS23
was located in the cell nucleus of breast cancer cells. Thus, we
used an RNAi knockdown approach to examine cancer cell
function could be affected by PRSS23 on breast cancer cell
proliferation. The efficacy of RNAi-mediated PRSS23 knock-
down was initially determined by immunoblot analysis (Fig. 7A).
We found that PRSS23 protein levels could be reduced by ,77%
in cells treated with RNAi directed against PRSS23 compared
with cells treated with the non-silencing control (NSC). After
confirming the PRSS23 knockdown, we used the PRSS23
knockdown MCF-7 cells in colony formation assays. The cells
were cultured in 0.4% soft agar with 10% fetal bovine serum
(FBS) without hormone deprivation for 6 days (Fig. 7B, upper
panel), and the size of each tumor particle was evaluated by
diameter. When sufficient E2 was present, the average diameter
of tumors formed in PRSS23 knockdown cells was 30% less than
the average diameter in NSC cells-forming tumors (p,0.01;
Fig. 7B, bar graph).
We also performed flow cytometry analysis to map the DNA
distribution profile of MCF-7 cells for cell cycle analysis. We
initially examined NSC control cells after 24 h stimulation with
20% FBS, either in the absence or presence of E2. Compared with
the ethanol vehicle-control cells, treatment with 1 nM E2
decreased cell counts at the G0/G1 phase from 35.91% to
32.20%, which represented a 10% reduction (Fig. 7C). In
addition, the S and G2/M phases each showed a 16.5%
(15.83%R18.45%) and a 9.7% (26.77%R29.41%) increase,
respectively, in the E2-treated cells compared with the control
cells.
After knockdown of PRSS23, the 1 nM E2 treatment still
caused an 11.4% decrease (32.82%R29.09%) in the G0/G1
phase; however, there was only showed a 6.6% increase
(17.17%R18.31%) in the S phase and a negligible 0.25%
reduction (22.83%R22.58%) in the G2/M phase. Thus, these
results indicate that PRSS23 is associated with E2–induced MCF-7
cell proliferation.
Discussion
The present study investigated which proteases were associated
with ERa in breast cancer. Bioinformatic analyses on breast
cancer microarray datasets published by van’t Veer et al. [21]
revealed that PRSS23 is one of the most highly expressed
proteases linked to ERa expression. Histopathological assays and
surveys of cancer cell lines further confirmed PRSS23 expression
was significantly increased in ERa-positive breast cancers, and
PRSS23 expression was upregulated by ERa-mediated transcrip-
tional regulation. We also investigated the functional role of
PRSS23 and found that PRSS23 may regulate DNA replication
PRSS23 in Breast Cancer Cells
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potential as a novel target for breast cancer therapy.
Proteases are known to play diverse roles in physiology and
pathology. Thus, it would not be surprising if some proteases
participated in estrogen-dependent breast tumor cell growth,
differentiation, and progression. For instance, cathepsin D
(CTSD), which is an estrogen-inducible lysosomal protease
identified in breast cancer, is considered to be a critical factor in
mediating apoptosis of cancer cells, neurodegeneration, and
development regression. Accumulating studies have provided
evidence that protein levels of CTSD are an independent
biomarker for better prognostic outcome in various cancers
[28,29,30,31,32,33]. In addition, the results reported in the
present study suggest that PRSS23 expression is upregulated by
estrogen-activated ERa in MCF-7 cells. Therefore, it is plausible
to hypothesize that protein levels of PRSS23 might also serve as an
independent prognostic factor for breast cancer. Due to case
number limited case numbers, we were not able to resolve the
underlying difference in PRSS23 and ERa across the various
subtype that could help to subtype breast cancers with distinct
prognostic outcomes; however, we were able to validate the
association between ERa status and high PRSS23 expression with
statistical confidence. Thus, when a sufficient number of breast
cancer cases are available, further investigation should be
undertaken to explore the importance of PRSS23 in breast cancer
patients with different ERa status and adjuvant chemotherapy.
Estrogen can stimulate the transactivity of ERa to upregulate
downstream gene expression either through direct binding to the
ERE in target genes or through coregulation with other
transcription factors [34,35]. Thus, it is interesting to determine
which route is involved in regulation of PRSS23 expression. Our
results from luciferase reporter assays indicate that E2 stimulates
PRSS23 expression in MCF-7 cells through the upstream
promoter region 22029 to 2342 bp. In addition, the ChIP assays
showed that E2 upregulates PRSS23 promoter activity by
activating ERa. Interestingly, previous studies have revealed that
DNA binding domain of ERa is dispensable for ERa-mediated
upregulation of PRSS23 gene expression in MCF-7 cells while E2 is
present [4]. According to our finding in the promoter activity assay
and ChIP assay, the promoter activity of PRSS23 gene induced by
E2 treatment is statistically significant (p,0.05) but not particularly
striking like that of canonical estrogen-induced genes, including
pS2 and CTSD. However, our results implied that PRSS23
expression is upregulated by ERa through not only the genomic
pathway but also other non-genomic pathway, which shall be
investigated in future studies. At least, these results suggest that
Figure 6. ERa upregulated PRSS23 expression through its upstream promoter region at 22029 to 2342 bp in MCF-7 cells. A. This
scheme depicts the pGL3-basic constructs containing the truncated PRSS23 promoters. Hormone-starved MCF-7 cells were separately transfected
with the constructs for 12 h in phenol-red-free medium containing 10% CDS-FBS. Transfected MCF-7 cells were treated with 10 nM E2 or vehicle
control (250 ppm ethanol) for 16 h in phenol-red-free medium containing 10% CDS-FBS. Level of relative luciferase units (RLUs) were normalized to
ethanol control. * p,0.05 and ** p,0.01 by the Mann-Whitney U test. B. Hormone-starved MCF-7 cells were treated with vehicle control (250 ppm
ethanol) or 10 nM E2 for 60 min. The binding of ERa to the upstream promoter region of the PRSS23 gene and the promoter of pS2 gene was
examined in a ChIP assay. Input control was 10% of original input cell lysate. NRS stands for nonspecific rabbit serum. These results are representative
of three individual experiments.
doi:10.1371/journal.pone.0030397.g006
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transcription factors at 22029 to 2342 bp in the promoter region
instead of the hypothetical ERE [23] in genomic pathway.
The anti-PRSS23 staining pattern in the immunohistochemical
studies of the patient specimens revealed that PRSS23 is found in
the cell nuclei of breast cancer cells and in normal stromal and
endothelial cells of peripheral tissues. The nuclear localization of
PRSS23 has been confirmed by subcellular fractionation studies
(unpublished data). Interestingly, another group used yeast two-
hybrid screening to show that PRSS23 might interact with
NCAPD3 (non-SMC Condensin II complex subunit D3), which
has been shown to play a significant role in mediating
chromosome condensation, segregation, and DNA repair during
S phase to prophase of the cell cycle [36,37,38]. Based on these
findings, we hypothesized that PRSS23 might be involved in
estrogen-driven mechanisms to mediate chromosome replication
of ERa-positive breast cancer cells. Although further investigation
is needed to resolve the detailed molecular mechanisms and
interactions involved, we propose that PRSS23 participates in the
regulation of breast cancer proliferation.
In conclusion, the present study demonstrated the close
relationship between PRSS23 and estrogen/ERa signaling in
breast cancer, which might serve as the basis for developing
PRSS23 into a novel prognostic or therapeutic target for breast
cancer.
Materials and Methods
Ethics statement
All human specimens were encoded to protect patient
confidentiality and processed under protocols approved by the
Institutional Review Board of Human Subjects Research Ethics
Committee of Mackay Memorial Hospital, Taipei City, Taiwan
and local law regulation. Breast cancer tissues along with their
Figure 7. PRSS23 knockdown reduced estrogen-driven MCF-7 cell proliferation. A. The PRSS23 knockdown efficacy in MCF7 cells treated
with nonspecific control (NSC) or PRSS23-specific RNAi was validated by immunoblotting. GAPDH was used as the loading control. The bar chart
shows the normalized protein level of PRSS23 in NSC and PRSS23 RNAi cells. B. The tumor sphere formation abilities of cells were evaluated in the
soft-agar tumor formation assay in the presence or absence of PRSS23 RNAi. The upper panel shows a representative picture of tumor sphere
formation in 0.4% soft-agar (scale bar is 200 mm). The bar chart shows that normalized diameter of examined tumors (n$50). The results are the
average of two individual experiments. C. After culturing in phenol-red-free medium containing 0.5% CDS-FBS for 48 h, the cells were stimulated
with 20% CDS-FBS and 1 nM E2 or 25 ppm ethanol for 24 h. The table shows the DNA distribution profile of the examined cells. Each value is the
average count of the cells in three individual experiments. * p,0.05 and ** p,0.01 by the Mann-Whitney U test.
doi:10.1371/journal.pone.0030397.g007
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bank of Mackay Memorial Hospital and reviewed and provided
without linkage to patients’ information by pathologists
(10MMHIS135). Written consents for placental tissue were
obtained from the patient for the present study (MMHIS137).
Cell culture, cell transfection and RNA interference
MCF-7, MDA-MB-231, Hs.578t and Ca-SKi cells were
cultured in RPMI 1640 medium (Cassion Laboratories, North
Logan, UT, USA) supplemented with 10% fetal bovine serum
(Invitrogen, Carlsbad, CA, USA), 2 g/l sodium bicarbonate,
15 mM HEPES, and 1 mM sodium pyruvate; T-47D were
cultured in medium supplemented with 0.2 U/ml insulin
(Sigma-Aldrich, St. Louis, MO, USA). BT-474 and RL95-2 cell
lines were cultured according to the instructions of American Type
Culture Collection. The MCF-10A cell culture has been
previously documented [39].
For transfections, plasmids were delivered with jetPRIME
transfection reagent (PolyPlus, Yvelines, France) according to the
manufacturer’s instructions. The RNAi knockdown system was
adopted from the pGIPZ vector–based lentivirus system (Open
Biosystems, Huntsville, AL, USA), and PRSS23 RNAi sequence is
59-ACCCAGATTTGCTATTGGATTA-39. The transfection
and transduction procedures followed the manufacturer’s instruc-
tions.
In estrogen treatment experiments, cultured cells were incubat-
ed in phenol-red-free RPMI1640 medium (Cassion Laboratories)
with 10% dextran-coated charcoal-stripped fetal bovine serum
(CDS-FBS) which was prepared with dextran-coated activated
charcoal (Sigma-Aldrich) according to the manufacturer’s instruc-
tions. 17b-estradiol (E2) and tamoxifen (Tam) were all purchased
from Sigma-Aldrich Corporation.
RNA isolation, cDNA synthesis and gene expression
quantitation
Total RNA was isolated using TRIzol reagent (Invitrogen)
according to the manufacturer’s instructions. cDNA was synthe-
sized using a SuperScript III reverse transcriptase kit (Invitrogen)
following the manufacturer’s instructions. Quantitative real-time
polymerase chain reaction (qRT-PCR) was carried out with SYBR
green PCR master mix (Applied Biosystems, Carlsbad, CA, USA)
using an ABI Prism 7500 sequence detector (Applied Biosystems)
following the manufacturer’s instructions. RPLP0 served as the
control for normalization [40]. The sequences of primer pairs are
showed in Table S2.
Cloning and site-directed mutagenesis
The open-reading frame of ESR1 (Addgene plasmid 11351
[41]) was subcloned into the pIRES-ZsGreen vector (Clontech,
Mountain View, CA, USA). The open-reading frame of PRSS23
was amplified by high-fidelity PCR (primers are listed in Table S1)
and cloned into the pIRES-ZsGreen1 vector (Clontech).
DNA fragments of the promoter region containing distal part of
exon 1 (22914 to 97 bp and 2391 to 97 bp) were separately
amplified by high-fidelity PCR of EcoRV-digested, genomic DNA
from human placenta tissue (primers are listed in Table S3). DNA
sequence analyses verified that the sequences were identical to
those published on the Entrez Genome Database, NCBI. DNA
sequences containing PRSS23 promoter ligated into the pGL3-
basic vector (Promega, Madison, WI, USA). There are two
available unique type-II restriction enzyme cutting sites in the
DNA fragment of the promoter–NdeI and PstI. The plasmid
pGL3-basic-PRSS23 promoter (22914 to 97 bp) was separately
digested by NheI and NdeI, NheI and PstI (New England BioLabs,
Ipswich, MA, USA) to generate the other two different constructs
of the PRSS23 promoter (i.e. 22029 to 97 bp, and 21261 to
97 bp, respectively).
Promoter luciferase reporter assay
For the luciferase reporter assay, 5610
4 cells were cotransfected
with the pCMV-Luc vector (Clontech) and pGL3-basic PRSS23
promoter constructs in 24-well plates. After overnight incubation,
cells were subcultured in 96-well plate (,1610
4 per well) and
treated with E2 for 16 hours. Luciferase activity was evaluated
using the Dual-Luciferase Reporter Assay kit (Promega) and the
VICTOR
3 multilabel plate reader (PerkinElmer, Waltham, MA,
USA).
Chromatin immunoprecipitation (ChIP) assay
The detailed ChIP procedures have been described by Fujita
et al. [42]. Briefly, immunoprecipitation of the DNA-protein
complexes was performed with 5 mg per sample of anti-ERa
(clone: F-10) (Santa Cruz Biotechnology, Santa Cruz, CA, USA)
and non-specific rabbit serum (Pierce Biotechnology, Rockford,
IL, USA). The target DNA fragment of each examined sample
was separately amplified by Phire Hot-Start DNA polymerase
(Finnzymes, Vantaa, Finland) with the primers of the PRSS23
promoter (21388 to 21149 bp), 59-CCCTTAAAATGGTG-
GAAAATATCAGTTTCC-39 and 59-TACATGAGAAAGCCC-
TGAACACATTATTGT-39, and pS2 ChIP PCR primers [43].
Membrane immunoblot
Immunoblot have been described in previous studies [44]. The
primary antibodies used in the present study were anti-ERa (clone:
F-10), anti-GAPDH (Santa Cruz Biotechnology) and the anti-
human PRSS23 antibody. The intensities of protein bands in
photographs were evaluated by ImageJ software.
Immunohistochemistry
The histological subtype of each tumor was determined after
surgery. The malignancy of infiltrating carcinomas was deter-
mined according to the Scarff-Bloom-Richardson classification
[45]. The staining procedures were according to Li et al. [46], and
images were captured by a TE-2000-E microscope equipped with
Nikon D50 digital camera (Nikon, Tokyo, Japan). The intensity of
PRSS23 expression in sections was scored following the guidelines
of the Allred scoring system [22]. Total Allred scores of samples
were analyzed with Fisher’s exact test to assess differences between
the pathological parameters. Classification of HER2 amplification
in breast cancer was performed according to Ellis et al. at 2005
[47].
Soft-agar colony formation assay
We performed soft agar colony formation assays using low
melting temperature agarose, as previous described (Sigma-
Aldrich) [48]. The images were captured randomly by TE-2000
inverted microscope equipped with Nikon D50 digital camera
(Nikon). The size of tumor was all measured in diameter. The
mean tumor sizes of different experiments were all normalized to
that of the control group.
Flow cytometry
The examined cells were harvested by 0.05% trypsin-EDTA
solution (Invitrogen). After washed with ice-cold 1X PBS thrice,
the cells were fixed with ice-cold 75% ethanol at 4uC for 1 h. The
cells were stained in a 1X PBS solution containing 6.7 mM
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30 min, and then analyzed in FACSCalibur (BD, Bedford, MA,
USA).
Statistics and data analysis
Microarray data of breast cancer patients were manipulated in
MySQL software, and clustering and organization of gene
expression were processed with Cluster software from the Eisen
lab [49]. The self-organized map was produced by TreeView
software. The descriptive statistics of the experimental data were
analyzed with Student’s t test, the Mann-Whitney U test, and
Fisher’s exact test in the R statistical program.
Supporting Information
Figure S1 MCF-7 cells was transfected with ectopic
PRSS23 and its expressed was detected by anti-PRSS23
with 20 mg lysate protein/well. PRSS23 displayed an
estimated molecular weight around 47 kDa (indicated by black
arrow).
(TIF)
Figure S2 Immunohistochemical characterization of
anti-PRSS23 staining. A. High PRSS23 expression: intensity
of nuclear staining of breast cancer cells (black arrow) higher than
the intensity of stained peripheral stromal cell (white arrow). B.
Moderate PRSS23 expression: intensity of nuclear staining of
breast tumor cells (black arrow) are equal to the intensities of
stained peripheral stromal cells (white arrow) and endothelial cells
(blue arrow). C. Low PRSS23 expression: intensity of nuclear
staining of breast cancer cells (black arrow) are higher than the
intensity of stained peripheral stromal cells (white arrow). Scale bar
is 200 mm.
(TIF)
Materials and Methods S1 Anti-PRSS23 Production.
(DOC)
Table S1 The primer list of the PRSS23 cloning.
(DOC)
Table S2 The primer list of qRT-PCR.
(DOC)
Table S3 The primer list for promoter cloning of
PRSS23 gene.
(DOC)
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